Autoimmune hemolytic anemia medical therapy: Difference between revisions

	Autoimmune hemolytic anemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune hemolytic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune hemolytic anemia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune hemolytic anemia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune hemolytic anemia medical therapy
CDC on Autoimmune hemolytic anemia medical therapy
Autoimmune hemolytic anemia medical therapy in the news
Blogs on Autoimmune hemolytic anemia medical therapy
Directions to Hospitals Treating Autoimmune hemolytic anemia
Risk calculators and risk factors for Autoimmune hemolytic anemia medical therapy

Revision as of 01:23, 12 February 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

@@ Line 9: / Line 9: @@
 ==Medical Therapy==
-Much literature exists regarding the treatment of AIHA. Efficacy of treatment depends on the correct diagnosis of either warm or cold type AIHA.
-The aim of therapy may sometimes be to lower the use of steroids in the control of the disease. In this case, [[splenectomy]] may be considered, as well as other immunosuppressive drugs. Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).<ref>{{cite journal |author=Zecca M, Nobili B, Ramenghi U, ''et al.'' |title=Rituximab for the treatment of refractory autoimmune hemolytic anemia in children |journal=Blood |volume=101 |issue=10 |pages=3857–61 |year=2003 |month=May |pmid=12531800 |doi=10.1182/blood-2002-11-3547 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12531800}}</ref>
-Warm type AIHA is usually a more insidious disease, not treatable by simply removing the underlying cause. First line therapy for this is usually with [[corticosteroid|corticosteroids]], such as [[prednisolone]]. Following this, other immunosuppressants are considered, such as [[rituximab]], [[danazol]], [[cyclophosphamide]], [[azathioprine]] or [[cyclosporine]].
-Cold agglutinin disease is treated by avoiding the cold or sometimes with rituximab. Removal of the underlying cause is also important.
-Paroxysmal cold hematuria is treated by removing the underlying cause, such as infection.
 ==References==